Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 5/20 | 0.43 |
| ▸ | FNTB | P49356 | 5/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569344 | 0.89 | SLC22A12 (0.39) | MCL1FNTAFNTBPGGT1B | |
| SCHEMBL7047037 | 0.85 | FNTA (0.44) | MCL1FNTAFNTBPGGT1BCA1 | |
| Hydrochloric Acid SCHEMBL7569839 | 0.84 | MCL1 (0.43) | MCL1FNTAFNTBPGGT1BCA1 | |
| SCHEMBL7570553 | 0.83 | SLC22A12 (0.56) | — | |
| SCHEMBL6988653 | 0.82 | NSD2 (0.40) | MCL1CA1CA2 | |
| SCHEMBL7570638 | 0.80 | CYP19A1 (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL7570998 | 0.80 | NSD2 (0.43) | MCL1 | |
| SCHEMBL7576242 | 0.79 | AR (0.44) | FNTAFNTBPGGT1B | |
| SCHEMBL7572477 | 0.79 | FNTA (0.48) | FNTAFNTBPGGT1BCA1CA2 | |
| SCHEMBL7572092 | 0.78 | CYP19A1 (0.56) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | MCL1 1726/4885FNTA 1/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.